Printer Friendly

Molecular Biosystems receives two patents for its ultrasound contrast imaging technology.

SAN DIEGO--(BUSINESS WIRE)--Nov. 25, 1996--Molecular Biosystems Inc. (NYSE:MB)(MBI) Monday announced that the U.S. Patent and Trademark Office issued two patents related to its ultrasound contrast imaging agents which cover encapsulated gas microspheres comprising perfluorocarbon and other gases.

The first patent, U.S. 5,552,133, is titled "Method of making the Encapsulated Gas Microspheres useful as an Ultrasound Imaging Agent" and includes claims which are directed toward a new milling method for the manufacturing of encapsulated gas-filled microspheres.

This new manufacturing process could potentially allow the company to increase its rate of production of FS069 while substantially reducing the costs associated with manufacturing ultrasound contrast agents.

The second patent, U.S. 5,562,893, is titled "Gas-filled Microspheres with Fluorine Containing Shells," and covers ultrasound imaging agents which comprise hydrocarbon and perfluorocarbon gases, such as perfluoropropane, perfluorobutane, perfluoropentane within fluorine containing shells. The patent also contains claims directed to a method of making the contrast agents and a method of performing a diagnostic ultrasound when using the patented agents.

"The issuance of these patents further protects the company's strong patent position in contrast imaging technology," said Kenneth J. Widder, M.D., chairman and chief executive officer. "We are gratified to receive two more patents that provide enhanced protection for our continuing contrast agent development."

Molecular Biosystems, based in San Diego, is a leader in the development of ultrasound contrast agents for medical imaging. ALBUNEX, the first FDA-approved ultrasound imaging agent is currently marketed in the United States by Mallinckrodt Inc.

This news release contains forward-looking statements that involve risks and uncertainties. The company's actual manufacturing efficiency and patent position could differ materially from the company's expectations. Among the factors that could result in a materially different outcome are unexpected problems developing the milling method, challenges to the company's patent position and the inherent uncertainties involved in developing and manufacturing a new product.

CONTACT: Molecular Biosystems Inc., San Diego

Gerard A. Wills/Stephen F. Keane, 619/824-2212
COPYRIGHT 1996 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1996, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Nov 25, 1996
Previous Article:SyQuest's Plans to Acquire Nomai are Discontinued.
Next Article:Pacific Crest Capital reports bulk purchase of $17.7 million in commercial real estate loans.

Related Articles
Make medical imaging effervesce....
Molecular Biosystems receives patent for orally administered ultrasound contrast agent.
Investigator reports use of ultrasound contrast imaging agent, FS069, is associated with significant cost savings as a result of enhanced diagnostic...
Molecular Biosystems Reports First Quarter Financial Results.
U.S. Patent Office to Reconsider Validity of Nycomed Contrast Agent Patent.
U.S. Patent Office To Reconsider Validity of ImaRx Contrast Agent Patent.
OPTISON Off to a Solid Start in Ultrasound Imaging Market.
U.S. Patent Office Issues Final Rejection of Key Nycomed Patent.
Molecular Biosystems Issued Additional U.S. Patent On OPTISON.
Palatin Notifies MBI of its Intent To Discontinue Merger.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters